ERBB2 and triple-negative breast carcinoma: Not surprisingly, the missing information on SLN metastasis would result in no adjuvant chemotherapy for triple negative breast cancer and neither adjuvant chemotherapy nor target therapy for HER2 positive breast cancer, which would be expected to have a greater impact on prognosis than luminal breast cancer with adjuvant hormone therapy.